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Supplement

Simplified Regimens for Management of Neonates and
Young Infants With Severe Infection When Hospital
Admission Is Not Possible
Study Protocol for a Randomized, Open-label Equivalence Trial
AFRINEST (AFRIcan NEonatal Sepsis Trial) Group
Background: In resource-limited settings, most young infants with signs of
severe infection do not receive the recommended inpatient treatment with
intravenous broad spectrum antibiotics for 10 days or more because such
treatment is not accessible, acceptable or affordable to families. This trial
was initiated in the Democratic Republic of Congo, Kenya and Nigeria to
assess the safety and efficacy of simplified treatment regimens for the young
infants with signs of severe infection who cannot receive hospital care.
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Methods: This is a randomized, open-label equivalence trial in which 3600
young infants with signs of clinical severe infection will be enrolled. The primary outcome is treatment failure in 7 days after enrollment, which includes
death or worsening of the clinical condition on any day, or no improvement
in the clinical condition by day 4 of treatment. Secondary outcomes include
compliance with study therapy, adverse effects due to the study drugs and
relapse or death during the week after completion of treatment.
Discussion: The results of this study, along with ongoing studies in Pakistan
and Bangladesh, will inform the development of global policy for treatment
of severe neonatal infections in resource-limited settings.
Key Words: neonates, young infants, antibiotic treatment, sepsis,
severe infection
(Pediatr Infect Dis J 2013;32:S26–S32
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eonatal infections are responsible for 700,000–800,000 neonatal deaths that occur globally every year.1 Over 95% of all
neonatal and infant deaths due to infections occur in developing
countries, where rates of home delivery are high and unhygienic conditions during and after birth are common. Appropriate treatment of
neonatal infections could prevent the majority of infection-specific
deaths, making it one of most important child survival interventions.2
Currently, it is recommended that young infants (from birth up
to 2 months of age) with signs of severe infection be referred for inpatient care and treated with intravenous broad spectrum antibiotics such
as a combination of ampicillin and gentamicin for 7-10 days.3 The
efficacy of the recommended treatment in reducing the risk of death
of young infants with severe infections is well accepted. However,
most such infants in developing countries do not currently receive
inpatient care,4–7 largely because treatment is not readily accessible
or because hospitalization is not acceptable or feasible for families.
A technical advisory group organized by Save the Children/
Saving Newborn Lives, United States Agency for International
Development and World Health Organization (WHO) in London
in 2007 recommended large, well-designed studies to evaluate
simplified antibiotic regimens for treatment of neonatal sepsis outside hospital settings.8 Such regimens could include an optimal
combination of oral and intramuscular antibiotics or injectable to
oral “switch” regimens that would be feasible in weak health systems. As a result, 2 randomized trials, using a common protocol,
were initiated in Pakistan and Bangladesh. A similar trial in Africa
was required to support the development of global policy.
In 2009, WHO sent out a call for African sites interested in
conducting a randomized, open-label equivalence trial similar to
the ones initiated in Asia. Five sites in Africa were selected after an
external review process, one site each in Democratic Republic of
Congo (DRC) and Kenya and 3 sites in Nigeria (Ibadan, Ile-Ife and
Zaria) to take part in this trial using a common protocol. This article
describes the design of the Africa trial.
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OBJECTIVES
The goal of the study is to inform global policy on the use
of simplified antibiotic treatment regimens for young infants with
signs of clinical severe infection who cannot receive hospital care.
• Primary objective: To evaluate simpler antibiotic regimens for
provision of safe and effective treatment of 0- to 59-day-old
young infants with signs of clinical severe infection whose families do not accept or cannot access referral-level care, compared
with a combination of injectable penicillin and gentamicin injections for 7 days.
• Secondary objectives: To assess family acceptance of different
treatment options and compliance with them, and to document
health worker requirements in terms of time and costs for each
treatment regimen.

METHODS
Study Design
This is an individually randomized, open-label, multicenter
equivalence trial. The 5 sites in DRC, Kenya and Nigeria are following the same protocol, quality control and coordination mechanisms to contribute to an overall sample size.

Study Settings
Democratic Republic of Congo

The infant mortality and neonatal mortality rates in DRC are
97 per 1000 and 31 per 1000 live births, respectively.9 The study is
being conducted in rural areas of 4 health zones in North and South
Ubangi districts, in the province of Equateur, DRC. The population of
the study area is about 300,000. In the first year of the study, a total of
about 12,000 births were identified in the study population. The operational primary healthcare functions in the study area are embedded
within Health Zones; each Health Zone consists of between 100,000 to
250,000 inhabitants and has 1 general referral hospital. Health Zones
are typically divided into 8–24 Health Areas, each with 1 Health Centre that covers a population of 5000 to 10,000 inhabitants; 30 Health
areas are included in the study. Health centers are the primary site of
care, where skilled health providers and the community intersect, and
curative and health promotion activities are conducted. Each health
center is staffed by 1 trained nurse, who oversees the activities of community health workers (CHWs) (literate village volunteer workers),
who primarily engage in preventive and promotional activities.

Kenya

The infant mortality and neonatal mortality rates in Kenya
are 52 per 1000 and 31 per 1000 live births, respectively.10 The
study is being conducted in the counties of Busia, Bungoma and
Kakamega (in the districts of Busia, Butula, Bungoma West, Bungoma South, Bungoma East, Teso South, Teso North and Mumias)
in Western Kenya. The population of the study area is about
350,000. In the first year of the study, a total of about 13,000 births
were identified in the study population. Thirty-four clusters were
selected for the study; each cluster has 1 dispensary or health facility manned by 2 health workers. These health units do not normally
have inpatient services for all cadres of patients and are the level-2
health facilities as per the Ministry of Health classification.

Nigeria

The infant mortality and neonatal mortality rates in Nigeria are 75 per 1000 and 47 per 1000 live births, respectively.11 In
Nigeria, the study used a cadre of health workers called community health extension workers (CHEWs). CHEWs receive 2 years of
© 2013 WHO and BMGF
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training in government-supported training institutes in basic issues
on maternal and child health, child nutrition, treatment of infections,
immunization and environmental health, oral and mental health.
They are also trained and allowed to provide injectable therapy.
Ile-Ife. The study is being conducted in the Ife Central and
East Local Government Areas (Ile-Ife community), a semi-urban
community in Osun State, in Southwestern Nigeria. The estimated
population of study area is about 350,000. In the first year of the
study, about 11,000 births were identified. The rate of refusal of
hospital admission is very high, about 50%, usually for religious
and cultural reasons. Deliveries by skilled birth attendants are very
low, although booking at health facilities for antenatal care is high.
Ibadan. The study is being conducted in Ido and Lagelu periurban Local Government Areas of Oyo State in the south western part
of Nigeria. The population is mainly rural with some suburban areas,
and the study population under surveillance is about 200,000. In the
first year of the study, about 8000 births were identified. Financial
constraints are a barrier to referral to health services. Most women
attend antenatal clinics while pregnant either in government hospitals
or mission homes usually owned by traditional birth attendants; less
than 50% deliver in these government health facilities.
Zaria. The third study site in Nigeria is Zaria Local Government Area, located in the northern part of Kaduna State in the
North West geopolitical zone of Nigeria. It is made up of more
than 100 urban, peri-urban and rural settlements populated by
predominantly Hausa/Fulani Muslims. The study population of
approximately 150,000 is located in 8 wards in the old, traditional
part of Zaria Town. In the first year of the study, about 6000 births
were identified. Although more than half the women attend antenatal clinics during pregnancy, less than 10% deliver in health facilities or under the supervision of trained attendants. Although home
delivery is the norm, less than half of these home births are supervised by a traditional birth attendant.

Study Participants
A summary of site description and implementation strategy
is given in Table 1 and the overall study approach in Figure 1.

Identification of Pregnancies and Births, Surveillance
for Illness

A pregnancy surveillance system has been established in all 5
study sites, with the aim of identifying newborns as soon as possible
after birth. CHWs in DRC and Kenya, and CHEWs in Nigeria, visit
all identified births on days 1, 3, 7, 14, 21, 28, 35, 42, 49 and 60 after
birth. At each home visit, they assess the newborn for signs of illness
and counsel the families on recognition of these signs (stopped feeding well according to the mother, reported convulsions, fast breathing, severe chest indrawing, temperature of ≥38.0°C or <35.5°C,
movement only on stimulation, yellow soles or pus from umbilicus,
eye or skin). Young infants with any of these signs are advised to go
to a health center or hospital. Those who refuse referral or are unable
to go to a facility are assessed by a study health worker.

Screening and Enrollment

Screening and enrollment are conducted by enrollment
nurses. In DRC and Kenya, this takes place at the health center or
dispensary. In Nigerian sites, it takes place at the child’s home. Young
infants, 0–59 days of age, are eligible for inclusion in this study if:
• they have signs of clinical severe infection: not feeding well
on observation, movement only when stimulated, severe chest
indrawing and axillary temperature ≥38.0°C or <35.5°C;
www.pidj.com |
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TABLE 1. Summary of Site Description and Implementation Strategy
Democratic
Republic of Congo
Population
Identification of pregnancies
and births
Home visits for newborn care
Screening and study enrollment
Treatment
Injection and
provision (and 1 oral dose
daily assess- Second oral
ment to detect dose
worsening)
Outcome assessment blinded to
treatment allocation (on days
4, 8, 11 and 15 of enrollment and for confirmation of
worsening)
Supervision

Kenya

Nigeria-1
Ibadan

Nigeria-2
Ile-Ife

Nigeria-3
Zaria

300,000
CHW/TBA

350,000
CHW/TBA

200,000
TBA/CHEWs

350,000
TBA/CHEWs

150,000
TBA/CHEWs

CHW
Enrollment nurse

CHW
Enrollment nurse or
clinical officer

Auxiliary nurse

Health centre nurse

CHEW
Screening by CHEW
Enrollment by
enrollment nurse
CHEW

CHEW
Screening by CHEW
Enrollment by
enrollment nurse
CHEW

CHEW
Screening by CHEW
Enrollment by
enrollment nurse
CHEW

Observed by CHW Observed by CHW

Observed by CHEW

Observed by CHEW

Observed by CHEW

Outcome
assessment
nurse

Outcome
assessment nurse

Outcome
assessment nurse

Outcome
assessment nurse

Outcome
assessment nurse

Community
coordinator

Community
coordinator

Study
supervisor

Study
supervisor

Study
supervisor

TBA indicates traditional birth attendant.

• they have no exclusion criteria: very low weight (<1500 g at
the time of presentation), hospitalization for illness in the last
2 weeks or previous inclusion in the study, any sign of critical
illness (unconscious, convulsions, unable to feed at all, apnea,
unable to cry, cyanosis, dehydration, bulging fontanel, major
congenital malformations inhibiting oral antibiotic intake, active
bleeding requiring transfusion, surgical conditions needing hospital referral and persistent vomiting [defined as vomiting after 3
attempts to feed the baby within 30 minutes]);
• their parents do not accept hospital referral; and
• their parents give consent to participate in the study.

Randomization

The enrolled infants are classified into 2 age groups, 0–6
days and 7–59 days, and randomly assigned to 1 of the treatment
regimens. The unit of randomization is the individual infant with
randomization stratified by age group and study site. An age-stratified randomization scheme with block size of 8 was computer-generated off-site at WHO using STATA version 10.0 (STATA Corp
LP, College Station, TX) by a person not involved with the study.
For allocation concealment, treatment codes are printed on small
pieces of cardboard pieces which are then folded once and sealed in
sequentially numbered opaque envelopes (2 color-coded envelopes,
one each for 0–6 days and 7–59 days age groups).
In the Kenyan and Nigerian sites, randomization is done centrally by a designated person who keeps the randomization envelopes. The enrollment nurse calls this person at the time of enrollment of a new infant, who opens the next envelope according to
the age category and conveys the treatment allocation. This process
takes place by phone and is confirmed by short message service. In
DRC where mobile phone communication is not reliable, each facility where enrollment occurs is given a block of 8 envelopes for each
age group, and used blocks are regularly replaced so that a sufficient
number of envelopes are always available at the facility.

Intervention and Comparison Groups
• Treatment regimen A (reference treatment): injectable gentamicin once daily and injectable procaine penicillin once daily
for 7 days (14 injections in total);
• Treatment regimen B: injectable gentamicin once daily and oral
amoxicillin twice daily for 7 days (7 injections in total);
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• Treatment regimen C: injectable gentamicin once daily and
injectable procaine penicillin once daily for 2 days, thereafter
oral amoxicillin for 5 days (4 injections in total);
• Treatment regimen D: injectable gentamicin once daily and oral
amoxicillin twice daily for 2 days, thereafter oral amoxicillin
twice daily for 5 days (2 injections in total).
All treatments are given at a health facility or at home. The
injections are given once daily by a health worker at a facility or at
home, whereas oral medicines are given by the mother under the
supervision of CHWs at home. Daily assessments are conducted by
health workers to identify any worsening of the child’s condition.
Home visits to assess the outcome of the treatment are conducted
by independent outcome assessment nurses at days 4, 8, 11 and15
after enrollment to detect treatment failure or relapse.
The rationale for selection, dosages and durations of antibiotics is given in detail elsewhere in this supplement.12 The combination
of penicillin and gentamicin is used globally for treating presumed
sepsis in the both neonatal period group and the second month of
life.3,13–16 The combination of penicillin/amoxicillin and gentamicin
targets common neonatal pathogens such as Escherichia coli, other
enteric gram-negative rods and streptococci. The antibiotic dosages
for young infants enrolled in the study are injection procaine penicillin in a dose of 50,000 units/kg once daily IM, injection gentamicin
in the range 4.0–7.5 mg/kg/day once daily IM (depending on age
of the young infant) and oral amoxicillin in suspension in a dose of
100 mg/kg/day (less than 2 kg are given 75 mg/kg/day), divided in 2
equal doses. All treatment regimens are being used for 7 days.

Provision of Treatment

In DRC and Kenya, all injectable treatment is provided at a
health facility by the treatment nurse, who also provides the first daily
dose of oral therapy. Mothers observe the first dose being given and
are instructed to provide the second daily dose of oral amoxicillin at
home in the same manner. In Nigeria, the first treatment (injectable
or oral) after randomization is provided by the treatment nurse at the
child’s home. Treatment on subsequent days is provided by CHEWs.

Study Outcomes
An independent outcome assessment nurse visits enrolled
infants on days 4, 8, 11 and 15 after the day of the enrollment to
© 2013 WHO and BMGF
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Community-based surveillance for neonatal illness
Follow up of pregnancies, identification of births by CHWs/TBAs
Home visits by CHWs to identify "danger signs"* on Day 1, 3, 7, 14, 21, 28, 35, 42, 49, 60

Management of illness by a nurse or clinical officer
Sick young infant taken to health facility by CHW (or visited by Health Worker at home)
Examined for signs of possible serious infection by Health Worker
Hospital referral recommended and assisted if these signs present

Screening
If the family does not
accept referral, the
young infant is
classified as:

Critically ill
(see definition in
text)

Excluded from
study

Clinical severe infection
(Feeding poorly, moves only on
stimulation, severe chest
o
indrawing, temperature <35.5 C
or >38oC)

Informed consent to
participate in study by
the family

If family accepts
referral, follow up*

No signs of
clinical severe
infection

Excluded from
study

Enrollment and randomization
by age groups
<7 days and 7-59 days
(colour coded envelopes)

Treatment at health facility (or at home)
• Treatment for 7 days according to randomization code
• Injections given once daily by Health Worker at facility or at home
• Oral medicines given by mother under supervision of HW/CHW
• Daily assessment by Health Worker providing treatment to detect worsening

Independent Outcome assessment
• Outcome assessment by independent assessor (experienced nurse or physician)
• Scheduled outcome assessment at Day 4, 8, 11 and 15 after enrolment
• Additionally, confirmation of worsening when detected by treating health worker

*Only if families provide consent for this follow-up visit to document outcome

FIGURE 1. Overall study approach.
assess outcome. All outcome assessments are conducted at the
young infant’s home.

Primary Outcome
The primary outcome is treatment failure before or at
the day 8 visit. Treatment failure is defined by any one of the
following:
• Death.
• Clinical deterioration (hospitalization, emergence of any sign
of critical illness at any time or a new sign of clinical severe
© 2013 WHO and BMGF

infection after the day 2 visit or reemergence of a sign of clinical
severe infection on day 4 after initial disappearance).
• No improvement in clinical condition by day 4 (if there was a
single sign of clinical severe infection at enrollment, persistence
of the sign; if there were multiple signs at enrollment, persistence
of >1 sign).
• Not cured by day 8 (persistence of any sign of clinical severe
infection on day 8 of enrollment).
• Development of a serious adverse event (SAE) other than death
that is thought to be related to the study antibiotics, for example,
www.pidj.com |
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organ failure, anaphylactic reaction, severe diarrhea, disseminated and severe rash.

Secondary Outcomes
• Death between days 9–15 after enrollment.
• Relapse (after disappearance of all signs of clinical severe infection by day 8, emergence of any sign of critical illness or clinical
severe infection between days 9–15 after enrollment).
• Adherence to the allocated treatment between days 1–8.

Sample Size
In the absence of population-based incidence data, the
incidence of possible severe bacterial infection among neonates
and young infants was conservatively assumed to be about 5% in
Africa. This estimate was based on earlier studies conducted in
Bangladesh and India where about 10–15% of all newborns had an
illness with at least 1 sign of possible severe bacterial illness during
follow-up,7,17,18 and 2 studies with more specific diagnostic criteria
reported a lower incidence of possible severe bacterial infection
of 7–10%.17,18
The sample size calculations were performed based on
comparing the failure rates observed with treatment regimen A
(reference treatment regimen: injection penicillin and gentamicin
for 7 days) with the failure rates expected with the 3 experimental
treatment regimens. For each comparison, the point estimate of the
failure rate difference (experimental–reference treatment) between
the 2 treatment regimens and its 2-sided 95% confidence interval
will be calculated. The alternative treatment will be judged to be
“of similar effectiveness” to the reference treatment A (assumed
treatment failure rate 10%) if the upper bound of the 95% confidence interval of the difference lies below the allowed “similarity
margin” of +5%. The required sample size for 90% power to demonstrate the similarity of 2 treatments assuming that the true failure
rates with the reference treatment and the experimental treatment
regimens will be identical (assumed to be 10%) works out to be
760 “analyzable” infants per arm who would be included in the
prespecified per-protocol analysis. Assuming that approximately
15% of randomized infants will be excluded from the per-protocol
analysis for failure to adhere treatment, the required sample size is
900 infants for each treatment regimen (a total of approximately
3600 infants).

Data Collection
Data collection is done by CHWs/CHEWs during home visits and includes data on all births as well as deaths within the first
2 months of life. The CHWs/CHEWs also screen young infants for
illness. Data are collected on the paper-based standard case report
forms that have been extensively field tested and revised after pilot
testing. Enrollment nurses complete a screening form after examination for every sick young infant who was referred or brought
to them by CHW/CHEW. They complete a baseline information
form at enrollment for every enrolled infant. Daily treatment and
assessment records are maintained by the treating health worker.
The outcome assessment nurses complete an assessment form at
days 4, 8, 11 and 15 days after randomization and when an infant is
sent to them for assessment by the treating health worker because
of suspected worsening of clinical condition. Names or other identifiers of the infant and his/her family are not included on the study
forms. All completed forms are checked by study supervisors for
completeness before they are entered into the computer.
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Data Management
Individual sites are responsible for their own day-to-day data
management activities. Each individual site has its own data management team, including a data manager and team of data entry
clerks. At each site, the data entry clerks enter data from paper
forms into the data management system, which stores the data in a
data base. The data management system consists of a front-end and
a back-end. The front-end, prepared in C++, is the user interface
that the data manager and the data entry clerks use to interact with
the database, whereas the back-end in Structured Query Language
stores the database itself. All data are double-entered and discrepancies verified to remove data entry errors. The data manager then
proceeds to run range and consistency checks built into the data
management system. After resolving all range and consistency
errors in consultation with the data collection staff, the data manager checks for inconsistencies in information across different case
report forms using inbuilt checks and resolves them in consultation with the field coordinators and if necessary with the principal
investigators of the study.
The cleaned data are sent every month to the central data
coordination center at London School of Hygiene and Tropical
Medicine in London. Additional data quality checks are carried
out, and feedback is provided to the study sites on a monthly basis.

Analysis Plan
The primary analysis will be a combined analysis across
all the sites. Simple comparisons of means and proportions by
treatment group will be used to check whether the randomization
scheme has in fact resulted in baseline comparability of treatment
groups. The primary analyses will be for equivalence between the
reference treatment and the 3 experimental arms; it will consist of
the comparison of proportions of infants with treatment failure in
each treatment arm.
Analysis will be conducted on a per-protocol basis and on
an intention-to-treat basis. Although the former is more conservative to establish equivalence of treatment regimens and will be the
primary analysis for this study, the latter will take into account the
possibility of differences in adherence to treatment across treatment arms despite the best efforts of the research team. In order for
an enrolled infant to be included in the per-protocol analysis, he/
she should have received: (1) all antibiotic doses due to be received
for the first 3 days of treatment or by the time of treatment failure,
and (2) at least 50% of all scheduled doses of each antibiotic on
days 4 to 7 or by the time of treatment failure. Furthermore, for
inclusion in the per-protocol analysis, treatment outcome should
have been assessed among days 2–4, days 5–8 and vital status on
day 8 known.
Each experimental regimen will be compared with the reference regimen and the difference in the risk of treatment failure
together with 95% confidence intervals will be calculated. Analyses
will be performed with data from all sites combining the 2 age subgroups, adjusted for any baseline covariates which were unbalanced
at baseline and with the addition of dummy variables for site and
age group.
Subgroup analysis of primary and secondary outcomes will
be performed by age subgroups (0–6 days and 7–59 days at the
time of enrollment). Univariate and multivariate regression analyses will be undertaken to identify clinical predictors of treatment
failure and death despite antibiotic treatment.

Ethical Issues
Study Approvals

The trial protocol and all associated data collection instruments and consent forms were approved by the local Institutional
© 2013 WHO and BMGF
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Review Boards, the WHO Ethical Review Committee and the Institutional Review Board of the London School of Hygiene and Tropical Medicine. The trial was registered as ACTRN12610000286044
with Australian New Zealand Clinical Trials Registry. The trial follows Council for International Organizations of Medical Sciences
and Good Clinical Practice guidelines.

Informed Consent

Communities in all sites were introduced to the study before
initiation of enrollment. This was achieved through meetings with
community leaders and with community groups. Informed written
consent is obtained for the home visits for pregnancy and birth,
enrollment, treatment as well as for follow-up visits of nonenrolled
infants. Health workers were trained to facilitate referral through
counseling using integrated management of childhood illness guidance for assisting referral. Only babies whose families refuse referral and are willing to document this by witnessed signature/thumbprint are enrolled.

Monitoring of Potential Adverse Events

The families are asked to contact the CHW/CHEW if any
adverse events occur. In the case of a SAE, CHWs contact their
supervising CHW and CHEWs contacts their outcome assessment
nurse. The assessment nurse documents the adverse event and conveys this to the Community Coordinator/Supervisor. SAEs such as
death, hospitalization, unable to pass urine for 12 hours, anaphylactic reaction, severe dehydration due to diarrhea, injection abscess or
disseminated or severe rash are reported to WHO within 48 hours
of their occurrence. This information is also provided on a regular basis to the Data Safety Monitoring Board (DSMB) and ethics
committees.

Rescue Therapy

At any time during the study follow-up, young infants
identified as treatment failures according to the study protocol are
referred to a hospital. If the parents refuse to take the infant to the
hospital, the infant is offered rescue therapy (intramuscular ceftriaxone for 7 days).

Data Safety Monitoring Board

The DSMB is responsible for monitoring and assessing the
safety of the trial and consists of an epidemiologist, a statistician
and 1 clinician scientist/researcher from each of the 3 countries.
The DSMB convenes at least once a year in a face-to-face meeting,
which consists of both an open and a closed session. Two interim
analyses will be conducted: when one third of participants and
when two thirds of participants have been enrolled and treated.
The DSMB determined that the trial will be stopped or modified if an interim analysis shows that the proportion of neonatal
deaths between treatment and control groups differ by at least 2
standard errors with a P value of 0.01. Furthermore, termination or
modification may be recommended for any other perceived safety
concern based on clinical judgment, including but not limited to
a higher than anticipated rate for any component of the primary
endpoint or unexpected SAEs. For this purpose, the SAE forms are
sent to the DSMB on a quarterly basis.

Quality Assurance
Training of Health Workers

Training of health workers for the study was a 2-step process. Training sessions for “master trainers” from all sites were
held using the WHO/UNICEF Home Care for Newborns course,
the WHO/UNICEF Young Infant integrated management of childhood illness course (for study nurses) and a study-specific procedures course. These site-specific master trainers were experienced
© 2013 WHO and BMGF
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physicians and nurses; they subsequently trained all CHWs/
CHEWs and nurses employed by the study. All supervisors and site
coordinators were also trained in all courses.

Standardization

Extensive standardization exercises were conducted for each
cadre of study health workers. For CHW/CHEW standardization
sessions, we identified 5–10 eligible young infants in a community
or a nearby health facility and asked each CHW/CHEW to assess
these infants while being observed by a trained facilitator. Assessments included weighing the child, assessing danger signs (ability to feed, convulsions, elevated respiratory rate, chest indrawing,
high or low temperature, lethargy and yellow soles). The facilitator compared his/her findings with those of each health worker to
identify errors. After the exercise, the trainees were given feedback;
those needing further standardization were given targeted refresher
training.
The same standardization process was used for all staff,
including enrollment nurses, treatment nurses, outcome assessment
nurses, health center nurses, supervisors and coordinators. These
healthcare workers were all trained to identify signs of critical illness. Standardization exercises were conducted at the start of the
study and subsequently every 3–6 months for all health workers
to ensure that all of them assessed clinical signs in a similar way.

Supervision

Supervised, accompanied visits and independent, unaccompanied visits are carried out regularly by the supervisors. Principal
investigators and coinvestigators also make random visits to study
sites to check quality.

Site Monitoring

Monthly progress reports are prepared by all sites, sent to
the WHO coordinating center for the study and reviewed critically
on a monthly basis. Regular conference calls are held to discuss the
progress of the trial. Data-based monitoring, as well as verification
of SAE forms, is carried out by the data coordination center in collaboration with the WHO study coordination team.
WHO technical staff conducts at least 2 monitoring visits to
each site every year. A detailed structured review of study implementation is conducted at each visit. The key areas that are monitored included the recruitment rate, clinical practices such as identification of danger signs and critical signs, detection of treatment
failure as well as data management and overall study procedures.
All study documentation is checked. A proportion of completed
case report forms, all treatment failures and all adverse events are
reviewed. Recommendations arising from the site visit are discussed with the Principal Investigators at the sites and followed up
for action. Monitoring visits are also conducted by external monitors who are not associated with the study.

Project Coordination
The project is being coordinated by the WHO Department
of Maternal, Newborn, Child and Adolescent Health. Technical
advice is provided by a Technical Advisory Group, which includes
all principal investigators, the WHO coordination team and external experts, and convenes at least once a year in a face-to-face
meeting. London School of Hygiene and Tropical Medicine assists
in quality control through database monitoring, prepares necessary
reports for the DSMB, Trial Advisory Group and liaises with WHO
study coordination team.

Timeline
The enrollment of study participants began in April 2011 at
all study sites and is likely to be completed by May 2013.
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